Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Market Movers Today: Switch Inc (SWCH), Longfin Corp (LFIN), Cellectis SA (ADR) (CLLS), Adamas Pharmaceuticals Inc (ADMS), and More

Switch Inc (NYSE:SWCH) (The Motley Fool)
What happened: Shares of Switch (NYSE:SWCH) have gotten crushed today, down by 16% as of 12:20 p.m. EDT, after the data center specialist reported fourth-quarter earnings. Net losses were worse than expected. So what: Revenue in the fourth quarter came in at $99.3 million, which was just slightly shy of the $99.6 million in sales that analysts were modeling for.

Longfin Corp (NASDAQ:LFIN) (Yahoo Finance)
Longfin Corp. (LFIN): Shares are tumbling, down -31%. The blockchain tech firm revealed it is under SEC investigation for failing to disclose important information surrounding its recent IPO and several misstatements the company has made since then.

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart


Cellectis SA (ADR) (NASDAQ:CLLS) (Benzinga)
Cellectis S.A. shares climbed 10.6 percent to $34.00. Cellectis and Allogene Therapeutics intends to continue strategic cancer immunotherapy partnership which originally consisted of Pfizer and Cellectis.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) (Seeking Alpha)
Enrollment is underway in a Phase 3 clinical trial assessing Adamas Pharmaceuticals’ (ADMS +4.2%) GOCOVRI (amantadine) extended-release capsules in multiple sclerosis (MS) patients with walking impairment. The primary endpoint of the 540-subject study is timed 25 foot walk (T25FW) compared to placebo. Two once-daily doses (137 mg and 274 mg) will be evaluated. According to, the estimated completion date is September 2019. The FDA approved GOCOVRI in August 2017 for dyskinesia (uncontrolled movements) in Parkinson’s disease patients receiving levodopa-based therapy.